Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen

Pfizer and Valneva have added another plank of evidence in support of their Lyme disease vaccine candidate, revealing antibody levels remained elevated six months after the completion of dosing in a phase 2 clinical trial.